NCT07092410 2026-04-21
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Phase 4 Withdrawn
Clinical Trials
13 trialsNCT07504796 2026-04-21
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NYU Langone Health
Phase 4 Recruiting
NCT03340506 2026-04-20
Dabrafenib and/or Trametinib Rollover Study
Novartis
Phase 4 Recruiting
NCT07459543 2026-03-09
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Phase 4 Not yet recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT03673332 2026-01-22
EPITOP-01
Institut Paoli-Calmettes
Phase 4 Terminated
NCT07200544 2025-12-15
Meloxicam in Mohs Micrographic Surgery
University of Oklahoma
Phase 4 Recruiting
NCT06461442 2025-12-05
Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis
University of California, Davis
Phase 4 Enrolling by invitation
NCT06880848 2025-09-24
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
Jemincare
Phase 4 Completed
NCT06285370 2025-09-18
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Kyowa Kirin Co., Ltd.
Phase 4 Active not recruiting
NCT02626065 2025-09-15
PAIR
Hospices Civils de Lyon
Phase 4 Completed
NCT03715205 2025-08-29
Keynote-593
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT06499415 2025-05-11
CALM
Maastricht University Medical Center
Phase 4 Recruiting